<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04225156</url>
  </required_header>
  <id_info>
    <org_study_id>ARGX-113-1803</org_study_id>
    <secondary_id>2019-002101-21</secondary_id>
    <nct_id>NCT04225156</nct_id>
  </id_info>
  <brief_title>A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).</brief_title>
  <acronym>ADVANCE+</acronym>
  <official_title>A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX 113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>argenx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>argenx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label long-term multicenter phase 3 trial to evaluate the efficacy and safety&#xD;
      of ARGX-113 in adult patients with primary ITP.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2020</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of Adverse Events</measure>
    <time_frame>Up to 60 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of vital signs</measure>
    <time_frame>Up to 60 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of laboratory assessments</measure>
    <time_frame>Up to 60 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extent of disease control defined as the percentage of weeks in the trial with platelet counts of ≥50×10E9/L.</measure>
    <time_frame>Over the 52 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with overall platelet count response defined as achieving a platelet count of ≥50×10^9/L on at least 4 occasions at any time during the 52-week treatment period.</measure>
    <time_frame>Over the 52 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in platelet count at each visit.</measure>
    <time_frame>Up to 60 weeks, at each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For patients rolling-over from the ARGX-113-1801 trial with a platelet count of &lt;30×10^9/L: time to response is defined as the time to achieve 2 consecutive platelet counts of ≥50×10^9/L</measure>
    <time_frame>Up to 60 weeks, at each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of weeks in the trial with platelet counts of ≥30×109/L and at least 20×10E9/L above baseline.</measure>
    <time_frame>Over the 52 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In patients with baseline platelet count of &lt;15×10E9/L in the current trial (ARGX-113-1803), the percentage of weeks in the trial with platelet counts of ≥30×10E9/L and at least 20×10E9/L above baseline.</measure>
    <time_frame>Over the 52 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In patients with first exposure to efgartigimod: proportion of patients who achieve a sustained platelet response defined as achieving platelet counts of at least 50×10^9/L for at least 4 of the 6 visits between week 19 and 24 of the trial.</measure>
    <time_frame>Up to 5 weeks, between visit 19 and 24 of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In patients with first exposure to efgartigimod: proportion of patients in the overall population achieving platelet counts of at least 50x10^9/L for at least 6 of the 8 visits between week 17 and 24 of the trial.</measure>
    <time_frame>Up to 7 weeks, between visit 17 and 24 of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of receipt of rescue therapy (rescue per patient per month).</measure>
    <time_frame>Up to 60 weeks, at each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in concurrent ITP therapy.</measure>
    <time_frame>Up to 60 weeks, at each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of the WHO-classified bleeding events.</measure>
    <time_frame>Up to 60 weeks, at each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient reported Outcomes (FACIT-Fatigue) at planned visits.</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient reported Outcomes (Fact-Th6) at planned visits.</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Quality of Life (SF-36) at planned visits.</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADA) to efgartigimod.</measure>
    <time_frame>Up to 216 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of efgartigimod: serum concentration observed predose (Ctrough).</measure>
    <time_frame>Up to 60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics markers: total IgG.</measure>
    <time_frame>Up to 60 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Primary Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>efgartigimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receiving efgartigimod</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>efgartigimod</intervention_name>
    <description>Intravenous infusion of efgartigimod</description>
    <arm_group_label>efgartigimod</arm_group_label>
    <other_name>ARGX-113</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Ability to understand the requirements of the trial, to provide written informed&#xD;
             consent (including consent for the use and disclosure of research-related health&#xD;
             information), and to comply with the trial protocol procedures (including required&#xD;
             trial visits).&#xD;
&#xD;
          2. Patients enrolled in the ARGX-113-1801 trial who completed the 24-weeks trial period.&#xD;
&#xD;
          3. Women of childbearing potential must have a negative urine pregnancy test at baseline&#xD;
             before trial medication (infusion) can be administered. Women are considered of&#xD;
             childbearing potential unless they are postmenopausal (defined by continuous&#xD;
             amenorrhea) for at least 1 year with a follicle-stimulating hormone (FSH) of &gt;40 IU/L&#xD;
             or are surgically sterilized (ie, women who had a hysterectomy, a bilateral&#xD;
             salpingectomy, both ovaries surgically removed, or have a documented permanent female&#xD;
             sterilization procedure including tubal ligation). Follicle-stimulating hormone can be&#xD;
             used to confirm postmenopausal status in amenorrheic patients not on hormonal&#xD;
             replacement therapy.&#xD;
&#xD;
          4. Women of childbearing potential should use a highly effective or acceptable method of&#xD;
             contraception during the trial and for 90 days after the last administration of the&#xD;
             IMP. They must be on a stable regimen, for at least 1 month:&#xD;
&#xD;
               -  combined (estrogen and progestogen containing) hormonal contraception associated&#xD;
                  with inhibition of ovulation:&#xD;
&#xD;
                    -  oral&#xD;
&#xD;
                    -  intravaginal&#xD;
&#xD;
                    -  transdermal&#xD;
&#xD;
               -  progestogen-only hormonal contraception associated with inhibition of ovulation:&#xD;
&#xD;
                    -  oral&#xD;
&#xD;
                    -  injectable&#xD;
&#xD;
                    -  implantable&#xD;
&#xD;
               -  intrauterine device (IUD)&#xD;
&#xD;
               -  intrauterine hormone-releasing system&#xD;
&#xD;
               -  bilateral tubal occlusion&#xD;
&#xD;
               -  vasectomized partner (provided that the partner is the sole sexual partner of the&#xD;
                  trial participant and that aspermia was documented post-procedure)&#xD;
&#xD;
               -  continuous abstinence from heterosexual sexual contact. Sexual abstinence is only&#xD;
                  allowable if it is the preferred and usual lifestyle of the patient. Periodic&#xD;
                  abstinence (calendar, symptothermal, post-ovulation methods) is not acceptable&#xD;
&#xD;
               -  male or female condom with or without spermicide&#xD;
&#xD;
               -  cap, diaphragm, or sponge with spermicide.&#xD;
&#xD;
          5. Non-sterilized male patients who are sexually active with a female partner of&#xD;
             childbearing potential must use an acceptable method of contraception, ie, a condom.&#xD;
             Male patients practicing true sexual abstinence (when this is in line with the&#xD;
             preferred and usual lifestyle of the participant) can be included. Sterilized male&#xD;
             patients who have had a vasectomy with documented aspermia post-procedure can be&#xD;
             included. In addition, male patients are not allowed to donate sperm during this&#xD;
             period from signing of informed consent form, throughout the duration of the trial,&#xD;
             and for 90 days after the last administration of IMP. In addition to the above&#xD;
             criteria, for patients who want to continue receiving efgartigimod during an&#xD;
             additional 52-week treatment period (only applicable in case efgartigimod is not yet&#xD;
             commercially available for patients with primary ITP, or becomes available through&#xD;
             another patient program for patients with primary ITP)&#xD;
&#xD;
          6. Ability to understand the requirements of the additional 52-week treatment period of&#xD;
             the trial, to provide written informed consent (including consent for the use and&#xD;
             disclosure of research-related health information), and to comply with the trial&#xD;
             protocol procedures (including required trial visits).&#xD;
&#xD;
          7. Patient has completed a 52-week treatment period.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Introduction or continuation of non-permitted medications during the ARGX-113-1801&#xD;
             trial (such as anti-CD20 therapy, romiplostim, monoclonal antibodies, Fc fusion&#xD;
             proteins or live/live-attenuated vaccines).&#xD;
&#xD;
          2. Pregnant or lactating women, and those intending to become pregnant during the trial&#xD;
             or within 90 days after the last dosing.&#xD;
&#xD;
          3. Patients with known medical history of hypersensitivity to any of the ingredients of&#xD;
             efgartigimod.&#xD;
&#xD;
          4. Use of any other investigational drug or participation in any other investigational&#xD;
             trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antonio Guglietta, MD</last_name>
    <phone>+1 857-350-4834</phone>
    <email>Clinicaltrials@argenx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigator Site 0010037</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0010042</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0010040</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0430002</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0430003</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0320012</name>
      <address>
        <city>Brasschaat</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0320011</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0320014</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0320002</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3590001</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3590002</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 4200001</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 4200008</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 4200006</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 4200007</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0330009</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0330018</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0330008</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0330016</name>
      <address>
        <city>Périgueux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0490010</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0490008</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0360004</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0360006</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0360015</name>
      <address>
        <city>Győr</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>Clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0360010</name>
      <address>
        <city>Nyíregyháza</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0360014</name>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390014</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390020</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390015</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390010</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390011</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390018</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390019</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390009</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390016</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810015</name>
      <address>
        <city>Hirakata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810017</name>
      <address>
        <city>Iruma</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810022</name>
      <address>
        <city>Kashiwa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810018</name>
      <address>
        <city>Maebashi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810021</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810014</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810016</name>
      <address>
        <city>Shibukawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810023</name>
      <address>
        <city>Shimotsuke</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0310006</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0310005</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0480012</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0480013</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0480014</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0480026</name>
      <address>
        <city>Nowy Sącz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0480011</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0070006</name>
      <address>
        <city>Kaluga</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0070008</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0070007</name>
      <address>
        <city>Petrozavodsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0070013</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0070009</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0070015</name>
      <address>
        <city>Syktyvkar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0070012</name>
      <address>
        <city>Tula</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0070010</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340006</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340007</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340009</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340014</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340012</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340015</name>
      <address>
        <city>Pozuelo De Alarcón</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340013</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340004</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340011</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900003</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900006</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900015</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900016</name>
      <address>
        <city>Edirne</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900013</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900004</name>
      <address>
        <city>İzmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900010</name>
      <address>
        <city>Mersin</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900007</name>
      <address>
        <city>Sakarya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900017</name>
      <address>
        <city>Tekirdağ</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900019</name>
      <address>
        <city>Trabzon</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3800006</name>
      <address>
        <city>Mykolaiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0440008</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

